Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]

Effective new antibiotics are used sparingly to prevent resistance, which makes them commercially unviable for pharma companies. This "vicious circle" of low usage leading to low revenue actively disincentivizes the development of the very drugs needed to combat superbugs.

To prevent losing top scientific talent to administrative roles, the "Venture Catalyst" model pairs a scientist-founder with a dedicated business team. This allows the scientist to remain in the lab, focused on research, while the experienced partners handle finance, legal, and daily management.

When a vaccine successfully eliminates dominant bacterial strains (serotypes), it creates a niche for non-covered strains to emerge and cause disease. This phenomenon, "serotype replacement," means narrowly focused vaccines can become victims of their own success by shifting the landscape of infectious threats.

Investors are hesitant to fund antimicrobial resistance research because the field has been stuck for decades trying the same approaches—traditional antibiotics and vaccines—and expecting different results. A fundamental shift in scientific strategy is required to regain investor confidence and make progress against superbugs.

Unlike traditional approaches, Immunethep's vaccine doesn't kill bacteria. Instead, it neutralizes a virulence mechanism bacteria use to shut down the immune system. This restores the body's natural ability to fight infection, a novel strategy analogous to checkpoint inhibitors in oncology.

Even when AMR experts explain that the crisis could be deadlier than cancer, their own families dismiss it as an overreaction. This personal anecdote highlights the severe public awareness gap surrounding one of the world's most urgent health crises, even among those closest to the issue.

Immunethep received a flat rejection from a Big Pharma contact who said, "I don't believe in vaccines." By approaching someone else within the same organization, they secured their most valuable partnership. This shows a 'no' often reflects an individual's bias, not the company's official stance.

Immunethep's initial plan for a universal vaccine targeting many bacteria hit a regulatory wall. Authorities required proof of efficacy for every single serotype, making the clinical trial "gigantic" and unfeasible. This forced a strategic pivot to more focused, single-family bacteria vaccines to create a viable path to market.

Ten years ago, Portugal's biotech scene had strong research but lacked funding, infrastructure, and an entrepreneurial ecosystem. Today, it offers startups more capital, dedicated biotech parks, and better university tech transfer support, marking a significant evolution into a more viable hub for commercial biotech.